about
Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-Adalimumab with or without methotrexate in juvenile rheumatoid arthritis.Macrophage activation syndrome in juvenile systemic lupus erythematosus: a multinational multicenter study of thirty-eight patients.Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis.A survey of national and multi-national registries and cohort studies in juvenile idiopathic arthritis: challenges and opportunitiesEfficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study.EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part I: Overall methodology and clinical characterisation.The Paediatric Rheumatology International Trials Organisation provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis.An international registry on autoinflammatory diseases: the Eurofever experience.Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review.Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial.Validation of the auto-inflammatory diseases activity index (AIDAI) for hereditary recurrent fever syndromes.Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial.Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis.Current medical treatments for juvenile idiopathic arthritis.A randomized, double-blind, placebo-controlled trial of paracetamol and ketoprofren lysine salt for pain control in children with pharyngotonsillitis cared by family pediatricians.2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features.International research networks in pediatric rheumatology: the PRINTO perspective.Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.Outcome in juvenile onset systemic lupus erythematosus.Agreement between physicians and parents in rating functional ability of children with juvenile idiopathic arthritis.Clinical assessment in juvenile dermatomyositis.The Pediatric Rheumatology European Society/American College of Rheumatology/European League against Rheumatism provisional classification criteria for juvenile systemic sclerosis.Network in pediatric rheumatology: the example of the Pediatric Rheumatology International Trials Organization.Long-term safety, efficacy, and quality of life in patients with juvenile idiopathic arthritis treated with intravenous abatacept for up to seven years.Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy.Is it time to move to active comparator trials in juvenile idiopathic arthritis?: a review of current study designs.Criteria to define response to therapy in paediatric rheumatic diseases.Networking in paediatrics: the example of the Paediatric Rheumatology International Trials Organisation (PRINTO).Comparison of clinical features and drug therapies among European and Latin American patients with juvenile dermatomyositis.Emerging drugs to treat juvenile idiopathic arthritis.Impact of the European paediatric legislation in paediatric rheumatology: past, present and future.Juvenile idiopathic arthritis and malignancy.Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial.2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Coll2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatri2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric RheumatologyThe Phenotype and Genotype of Mevalonate Kinase Deficiency: A Series of 114 Cases From the Eurofever Registry.Agreement between multi-dimensional and renal-specific response criteria in patients with juvenile systemic lupus erythematosus and renal disease.Performance of Different Diagnostic Criteria for Familial Mediterranean Fever in Children with Periodic Fevers: Results from a Multicenter International Registry.
P50
Q27021322-B539D3BA-1188-4B08-9199-A5EE0DFFBC3BQ33361908-AD3180FF-14E6-40A1-9FD8-2D906B2DF371Q33386883-C46DDC48-4D96-4EC6-A4DD-38BA1ED24CF8Q33404895-95DE41D4-A931-4D7D-8351-49D3FDBBF6D3Q33576975-16696227-4AB2-4C12-9783-D435D393BA9EQ33659233-2583C650-9689-4966-8714-E7695640B99FQ34109962-FA474C5C-E7E1-4DF3-BBB0-7F233A528342Q34242363-1C1B3358-A9D5-4225-BA9B-28807CB83842Q34257724-638290F6-1E9F-49F0-A167-A588CA94B4FDQ34285481-9AFCDA27-1E5C-4D6D-8523-1E20FBB4830DQ34594335-339FB0AF-88E0-4655-AEE7-596DBFC07F0EQ34607687-BB264AF1-E60D-458A-857C-D4B77840325EQ34674692-F822F34A-2F4F-42F7-B7E7-0EBB28D9AAE2Q35165540-D5F2CA60-433C-4F3B-93A3-3B209623EA30Q35294398-B07E1AE6-4577-43A6-8528-467AB619FBF3Q35339212-A836F632-01BC-468D-844B-05B5F31EF7B4Q35567870-7DDBD038-7897-4B5A-90C8-EA21048CA05FQ35864701-75140494-F83B-4402-AF7A-EFF81CE3FAB0Q36116060-606D9557-FC87-47A5-9B08-39F31A3D0D4BQ36225769-5F631D68-DCFC-4A5C-B3B8-5BB7A5E46473Q36431906-E8078C26-F940-418B-B5C0-2B926711731CQ36504380-FCA84C23-9CFC-408A-8D92-306BEDAEF5ACQ36748226-0C2B93B5-2D44-4EC1-942A-6342C3974D84Q37281506-D4D9B98E-478B-4D19-9C24-89766B9FE3BFQ37320554-B9D3F049-3F3B-4AB9-9BBB-92A82E665DF5Q37602644-D27E4E05-E4E1-441C-A794-499717E911CCQ37775937-A59B8B0B-4EA1-43D7-AE46-61C2D64FD3AEQ37811971-A0021CB1-6D0E-42E0-BFF8-8EBC79E60BD5Q37840926-38672FB0-E4D0-4FEC-89B6-D6B8BAF1BF7CQ37846264-E55E2A74-6D62-4D1D-9D5B-C0FE079499B1Q37870209-2BFE1650-A747-43D4-A8FE-75C1DCCE11C2Q38130348-F8AC4230-B3A6-418A-881A-3054598D7D3BQ38159458-4CE68CA2-1DA4-4DDF-9ED0-A974AA585DABQ38374642-EE11D88B-0512-4199-9224-21CB68AF662EQ38575277-78EBBEA9-7633-429B-95CE-2E982234BB8BQ38849144-B0E7AA9D-46F0-4CB3-927A-075A95EA27E2Q38849148-8F830FD1-1BC2-4E73-9E69-EBCF6F207DA9Q39744124-29D65129-B1A2-4608-B8D5-E5CC391A12DBQ39870238-8C1D6A1C-4878-4CF0-A654-42F21DD0D4F8Q40130919-B0B7069D-C0DC-4540-A51B-1FE7AA3643EB
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Nicolino Ruperto
@ast
Nicolino Ruperto
@de
Nicolino Ruperto
@en
Nicolino Ruperto
@es
Nicolino Ruperto
@fr
Nicolino Ruperto
@it
Nicolino Ruperto
@nl
type
label
Nicolino Ruperto
@ast
Nicolino Ruperto
@de
Nicolino Ruperto
@en
Nicolino Ruperto
@es
Nicolino Ruperto
@fr
Nicolino Ruperto
@it
Nicolino Ruperto
@nl
prefLabel
Nicolino Ruperto
@ast
Nicolino Ruperto
@de
Nicolino Ruperto
@en
Nicolino Ruperto
@es
Nicolino Ruperto
@fr
Nicolino Ruperto
@it
Nicolino Ruperto
@nl
P106
P31
P496
0000-0001-8407-7782